Who Paid My Doc
Wesley Dutton
Obesity Medicine Boston, MA Medical Doctor
NPI 1972999654 CMS profile 6082189
50 Staniford St Ste 430, Boston, MA 02114
General payments
$510
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Wesley Dutton of Boston, MA is reported in the CMS Open Payments database as having received $510 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 41st percentile of Obesity Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $121 | 1 | |
| 2023 | General | $389 | 3 |
Beside peers
- Wesley Dutton
- Obesity Medicine median
- Middle half of Obesity Medicine
- National median
In program year 2025, general payments to Wesley Dutton were reported at $0. Among 72 Obesity Medicine profiles paid that year, the median was $191 and the middle half received between $116 and $2,515.
Show as a table
| Year | Wesley Dutton | Obesity Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $224 | $90–$564 | $163 |
| 2020 | $0 | $118 | $51–$1,043 | $114 |
| 2021 | $0 | $195 | $98–$1,394 | $132 |
| 2022 | $0 | $223 | $87–$754 | $149 |
| 2023 | $389 | $228 | $103–$1,114 | $160 |
| 2024 | $121 | $150 | $83–$471 | $164 |
| 2025 | $0 | $191 | $116–$2,515 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
560
Drug cost
$430,503
Branded share of claims
75.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 91 | $146,545 | |
| Mounjaro Tirzepatide | Brand | 81 | $139,102 | |
| Wegovy Semaglutide | Brand | 45 | $79,772 | |
| Trulicity Dulaglutide | Brand | 38 | $58,790 | |
| Naltrexone Hcl | Generic | 35 | $2,027 | |
| Metformin Hcl Er Metformin Hcl | Brand | 144 | $1,873 | |
| Topiramate | Generic | 74 | $1,568 | |
| Bupropion Xl Bupropion Hcl | Brand | 22 | $585 | |
| Metformin Hcl | Generic | 30 | $242 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$20,197
Medicare patients
118
Services billed
185
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 60% | |
| Depression | 47% | |
| Arthritis | 46% | |
| Diabetes | 36% | |
| Heart failure | 22% | |
| Ischemic heart disease | 21% | |
| Chronic kidney disease | 19% | |
| Atrial fibrillation | 13% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obesity Medicine in Massachusetts
Related records
Obesity Medicine in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Obesity Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.